Our results strongly suggest that siRNA RET/PTC3-SQ NPs could be accredited as a potential new pharmacological approach for papillary thyroid carcinoma with RET/PTC3 junction oncogene. The gene discussed is NCOA4; the disease is thyroid gland papillary carcinoma.